以岭药业(002603) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥1,760,955,184.28, a decrease of 1.30% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥24,319,734.26, down 84.07% year-over-year[3]. - The net profit excluding non-recurring gains and losses was ¥2,571,866.06, a decline of 97.41% compared to the previous year[3]. - Total operating revenue for Q3 2024 was CNY 6,365,441,001.17, a decrease of 25.6% compared to CNY 8,574,678,320.29 in the same period last year[15]. - Net profit for Q3 2024 was CNY 549,086,852.74, a decline of 68.7% compared to CNY 1,753,936,733.34 in Q3 2023[16]. - The total comprehensive income for the third quarter was approximately CNY 549.64 million, a decrease from CNY 1.75 billion in the same period last year[17]. - Basic and diluted earnings per share for the quarter were CNY 0.3321, compared to CNY 1.0527 in the previous year[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥16,614,084,710.98, representing a decrease of 2.15% from the end of the previous year[3]. - The company's total assets decreased to CNY 16,614,084,710.98 from CNY 16,979,326,536.89 year-over-year, reflecting a reduction of 2.1%[14]. - Total liabilities decreased to CNY 5,128,442,387.30 from CNY 5,541,331,336.92, a reduction of 7.4% year-over-year[14]. - Long-term borrowings increased to CNY 667,102,581.96 from CNY 599,100,000.00, representing an increase of 11.4%[14]. Cash Flow - Cash flow from operating activities was ¥322,629,831.08, an increase of 123.08% compared to the same period last year[7]. - Cash inflow from operating activities was CNY 5.6 billion, down from CNY 7.66 billion year-on-year, indicating a decline of approximately 26.9%[18]. - The net cash flow from operating activities was CNY 322.63 million, an increase from CNY 144.62 million in the previous year[19]. - Cash outflow from investing activities totaled CNY 2.15 billion, compared to CNY 4.12 billion in the previous year, reflecting a decrease of approximately 47.9%[19]. - The net cash flow from financing activities was negative CNY 307.89 million, a decline from a positive CNY 147.18 million in the previous year[19]. - The cash and cash equivalents at the end of the period amounted to CNY 861.24 million, down from CNY 991.60 million at the end of the previous year[19]. - The company reported a decrease in cash paid to employees, totaling CNY 1.51 billion, compared to CNY 1.79 billion in the previous year[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 189,795[8]. - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of the shares, totaling 526,775,963 shares[8]. - The second-largest shareholder, Wu Xiangjun, holds 20.81% of the shares, totaling 347,728,119 shares, with 260,796,089 shares pledged[8]. - The total number of preferred shareholders with restored voting rights is not applicable[8]. Other Financial Metrics - The weighted average return on equity was 0.27%, down 1.25% year-over-year[3]. - The company reported a significant decrease in financial expenses, which rose to ¥25,657,133.42, an increase of 171.42% year-over-year[7]. - The company’s contract liabilities decreased by 39.65% to ¥173,514,006.27 due to a reduction in advance payments received[7]. - The company’s other payables increased by 609.11% to ¥306,333,411.48, primarily due to accrued dividends[7]. - The company’s investment income increased by 228.64% to ¥501,146.91, attributed to gains from trading financial assets[7]. - Research and development expenses for Q3 2024 amounted to CNY 571,912,835.78, slightly down from CNY 593,708,782.64 in the previous year[16]. Inventory and Receivables - Accounts receivable increased to ¥2,778,342,773.44 from ¥2,401,186,364.09 at the beginning of the period[12]. - Inventory decreased to ¥1,940,905,922.51 from ¥2,458,692,034.90 at the beginning of the period[12]. - The company has a trading financial asset balance of ¥9,000,000.00, down from ¥205,968,611.11 at the beginning of the period[12]. - The company reported a significant increase in prepayments to ¥148,349,186.50 from ¥109,711,768.30 at the beginning of the period[12]. Audit and Reporting - The company has not undergone an audit for the third quarter report[20]. - The report was released by the board of directors on October 29, 2024[21].